Express Pharma

STADMED to focus more on the domestic market


The company has launched 20 new brands including brand’s extensions

Asheesh Roy

Kolkata-based pharmaceutical company STADMED has achieved remarkable growth in the last three years. Stadmed is focusing more on the domestic market to catch up with the growth driven by the small and mid sized Indian pharma companies.

In recent past, the company has launched 20 new brands including brand’s extensions, out of which 12 brands are successfully growing and competing strongly with the leaders to enhance the market share. It has created more rural headquarters to increase its reach to various types of medical practitioners.

The company is aiming to increase its prescriber base and area of operation in domestic retail pharma market. Stadmed is growing rapidly in Andhra Pradesh and Telengana and has objectives to operate in these states in full capacity by the year end.

Research and development and formulations are the other areas the company has focused upon. Stadmed successfully developed innovative release method in specific drug category viz. pain, nutrition supplement, sedative hypnotics etc. The company is dedicated to provide quality medicines since seven decades. Growing demand and growth in business has been a challenge for the company to meet.

With a field force of 400, the company is able to retain its talents. Formation of different strategic business unit (SBU) and segment-wise promotion is the motto of the company. At present, the company has two SBUs and has plans to increase it by four in the next couple of years. The represented product market is immensely potential and addition of brands in urology, paediatrics and in chronic care segments have strengthened the product portfolio.

Asheesh Roy, Director Sales and Marketing, Stadmed says, ‘We are optimistic to reach newer heights within the next few years. The rich experience and market image of the company will drive us faster to achieve the Rs 200-crore. mark sooner. The unique drug delivery system in recently launched ‘Urifur-SR’ (Nitrofurantoin sustained release tablet) has given us success for better patient compliance at most affordable price. We are aiming to create more SBUs for more focused promotion.’”

EP News BureauKolkata

- Advertisement -